Digital pathology player Proscia procures $37M to expand its reach

Shortly after garnering a European green light for its digital pathology platform, the software developer Proscia has posted a $37 million venture capital round to help expand its commercial reach and seek additional product approvals.

The company previously collected $23 million in a late 2020 series B cycle. Its Concentriq Dx platform for analyzing tissue slides aims to bring together Proscia’s in-house portfolio of artificial intelligence tools, as well as plug-and-play offerings from third-party software developers, and combine them in one workflow to help clinicians check patient samples for diseases such as cancer.